Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

Yıl: 2022 Cilt: 39 Sayı: 1 Sayfa Aralığı: 43 - 54 Metin Dili: İngilizce DOI: 10.4274/tjh.galenos.2021.2021.0287 İndeks Tarihi: 21-06-2022

Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

Öz:
Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARSCoV- 2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixtynine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.
Anahtar Kelime:

COVID-19 Geçiren Türk Hematolojik Malignite Hastalarının Klinik Özellikleri ve Sonuçları

Öz:
Amaç: Solid malignite hastalarının şiddetli akut solunum yolu enfeksiyonu-koronavirüs-2 (SARS-CoV-2) enfeksiyonuna sağlıklı bireylerden daha yatkın oldukları gösterilmiştir. Bu verilerin ardından oldukça yoğun immünosupresif olan hematolojik malignite hastalarında SARS-CoV-2 infeksiyonu sonuçları ilgi konusu olmuştur. Biz de bu makalede Türkiye’de hematolojik malignite tanısı ile takip ve tedavi edilirken SARS-CoV-2 enfeksiyonu saptanan hastaların semptom, komplikasyon, yoğun bakım ünitesine yatış ve mortalite oranlarını değerlendirmeyi amaçladık. Gereç ve Yöntemler: Çok merkezli çalışmamıza Mart-Kasım 2020 tarihleri arasında SARS-CoV-2 enfeksiyonu tanısı alan erişkin ve pediatrik 340 hastayı dahil ettik. Hastaların hematolojik malignite tanıları, hastalık statusları, tedavileri, son tedaviden enfeksiyona kadar geçen süre, komorbiditeleri, yaşam beklentileri değerlendirildi. Semptomları, oluşan komplikasyonlar ve sonuçlar analiz edildi. Bulgular: Kırk-dört hasta semptomsuz olarak enfeksiyonu geçirirken, semptomatik hastaların ateş, öksürük, ve dispne oranları sırasıyla %62,6, %48,8 ve %41,8 idi. Altmış altı hasta (%20) hastalığı hafif geçirirken, orta, ciddi ve kritik hastalık tanısı alanların oranı sırasıyla %29, %20 ve %16 idi. Tüm kohortta ölüm oranı %26,6 idi; ölüm hafif hastalığı olanlarda %4,4 , orta derece hastalık geçirenlerde %12 ve ciddi/kritik hastalık geçirenlerde ise %83 olarak saptandı. Aktif hematolojik hastalık olması, primer hematolojik hastalığa bağlı düşük hayat beklentisi, SARS-CoV-2 tanısı aldığında nötropenik olmak, yoğun bakıma alınmış olmak ve ilk sıra koronavirüs hastalığı-2019 tedavisi yüksek ölüm riski ile ilişkilendirilen faktörlerdendi. Tek başına veya azitromisin ile kombine olarak hidroksiklorokin kullanan hastaların sadece favipiravir kullananlara göre ölüm riskleri daha yüksek saptandı. Sonuç: SARS-CoV-2 infeksiyonu geçiren hematolojik malignite hastalarında daha yüksek oranda ciddi hastalık ve ölüm riski gözlenmektedir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Bloomgarden ZT. Diabetes and COVID-19. J Diabetes 2020;12:347-348.
  • 2. Rodgers GP, Gibbons GH. Obesity and hypertension in the time of COVID-19. JAMA 2020;324:1163-1165.
  • 3. Fernández-Fernández FJ. COVID-19, hypertension and angiotensin receptor-blocking drugs. J Hypertens 2020;38:1191.
  • 4. Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. Eur Respir J 2020;56:2002108.
  • 5. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, Xiong Y, Xiong H, Wang C, Chen C, Xiong F, Zhang Y, Peng Y, Ge S, Zhen B, Yu T, Wang L, Wang H, Liu Y, Chen Y, Mei J, Gao X, Li Z, Gan L, He C, Li Z, Shi Y, Qi Y, Yang J, Tenen DG, Chai L, Mucci LA, Santillana M, Cai H. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 2020;10:783-791.
  • 6. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335-337.
  • 7. Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020;21:e180.
  • 8. Fontana L, Strasfeld L. Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient. Infect Dis Clin North Am 2019;33:523-544.
  • 9. Khawaja F, Chemaly RF. Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies. Haematologica 2019;104:1322-1331.
  • 10. Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 2020;34:2354-2363.
  • 11. World Health Organization. WHO Interim Guidance. Clinical Management of COVID-19. Geneva, WHO, 2020.
  • 12. Yigenoglu TN, Ata N, Altuntas F, Bascı S, Dal MS, Korkmaz S, Namdaroglu S, Basturk A, Hacıbekiroglu T, Dogu MH, Berber İ, Dal K, Erkurt MA, Turgut B, Ulgu MM, Celik O, Imrat E, Birinci S. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol 2021;93:1099-1104.
  • 13. Piñana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G, Gómez-Catalan I, Coll R, De La Fuente I, Luna A, Merchán B, Chinea A, de Miguel D, Serrano A, Pérez C, Diaz C, Lopez JL, Saez AJ, Bailen R, Zudaire T, Martínez D, Jurado M, Calbacho M, Vázquez L, Garcia-Cadenas I, Fox L, Pimentel AI, Bautista G, Nieto A, Fernandez P, Vallejo JC, Solano C, Valero M, Espigado I, Saldaña R, Sisinni L, Ribera JM, Jimenez MJ, Trabazo M, Gonzalez-Vicent M, Fernández N, Talarn C, Montoya MC, Cedillo A, Sureda A; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol 2020;9:21.
  • 14. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39:405-407.
  • 15. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG, Fracchiolla N, Ladetto M, Gambacorti Passerini C, Salvini M, Marchetti M, Lemoli R, Molteni A, Busca A, Cuneo A, Romano A, Giuliani N, Galimberti S, Corso A, Morotti A, Falini B, Billio A, Gherlinzoni F, Visani G, Tisi MC, Tafuri A, Tosi P, Lanza F, Massaia M, Turrini M, Ferrara F, Gurrieri C, Vallisa D, Martelli M, Derenzini E, Guarini A, Conconi A, Cuccaro A, Cudillo L, Russo D, Ciambelli F, Scattolin AM, Luppi M, Selleri C, Ortu La Barbera E, Ferrandina C, Di Renzo N, Olivieri A, Bocchia M, Gentile M, Marchesi F, Musto P, Federici AB, Candoni A, Venditti A, Fava C, Pinto A, Galieni P, Rigacci L, Armiento D, Pane F, Oberti M, Zappasodi P, Visco C, Franchi M, Grossi PA, Bertù L, Corrao G, Pagano L, Corradini P; ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020;7:e737-e745.
  • 16. García-Suárez J, de la Cruz J, Cedillo Á, Llamas P, Duarte R, Jiménez-Yuste V, Hernández-Rivas JÁ, Gil-Manso R, Kwon M, Sánchez-Godoy P, Martínez- Barranco P, Colás-Lahuerta B, Herrera P, Benito-Parra L, Alegre A, Velasco A, Matilla A, Aláez-Usón MC, Martos-Martínez R, Martínez-Chamorro C, Susana-Quiroz K, Del Campo JF, de la Fuente A, Herráez R, Pascual A, Gómez E, Pérez-Oteyza J, Ruiz E, Alonso A, González-Medina J, Martín-Buitrago LN, Canales M, González-Gascón I, Vicente-Ayuso MC, Valenciano S, Roa MG, Monteliu PE, López-Jiménez J, Escobar CE, Ortiz-Martín J, Diez-Martin JL, Martinez-Lopez J; Asociación Madrileña de Hematología y Hemoterapia (AMHH). Impact of hematological malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population based registry study. J Hematol Oncol 2020;13:133.
  • 17. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martin Moro F, Razanamahery J, Riches JC, Zwicker JI, Patell R, Vekemans MM, Scarfo L, Chatzikonstantinou T, Yildiz H, Lattenist R, Mantzaris I, Wood WA, Hicks LK. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and -analysis of 3377 patients. Blood 2020;136:2881-2892.
  • 18. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, Wu D, Liang B, Lu X, Ma Y, Li L, Wang H, Chen Z, Li Q, Gale RP. COVID-19 in persons with haematological cancers. Leukemia 2020;34:1637-1645.
  • 19. Malard F, Genthon A, Brissot E, van de Wyngaert Z, Marjanovic Z, Ikhlef S, Banet A, Lapusan S, Sestilli S, Corre E, Paviglianiti A, Adaeva R, M’Hammedi- Bouzina F, Labopin M, Legrand O, Dulery R, Mohty M. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant 2020;55:2180- 2184.
  • 20. Martín-Moro F, Marquet J, Piris M, Michael BM, Sáez AJ, Corona M, Jiménez C, Astibia B, García I, Rodríguez E, García-Hoz C, Fortún-Abete J, Herrera P, López-Jiménez J. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol 2020;190:e16-e20.
  • 21. Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong KL, Hungria VTM, Engelhardt M, Gay F, Garcia-Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum CA, Kumar SK, Stadtmauer E, Einsele H, Beksac M, Weisel KC, Anderson KC, Mateos MV, Moreau P, San Miguel J, Munshi NC, Avet-Loiseau H. Clinical features associated with COVID-19 outcome in MM: first results from International Myeloma Society Dataset. Blood 2020;36:3033-3040.
  • 22. Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ntanasis-Stathopoulos I, van de Donk NWCJ, Avet-Loiseau H, Hajek R, Vangsted AJ, Ludwig H, Zweegman S, Moreau P, Einsele H, Boccadoro M, San Miguel J, Dimopoulos MA, Sonneveld P. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia 2020;34:2000-2011. 23. Ferrara F, Zappasodi P, Roncoroni E, Borlenghi E, Rossi G. Impact of Covid-19 on the treatment of acute myeloid leukemia. Leukemia 2020;34:2254-2256.
  • 24. Sahu KK, Siddiqui AD, Cerny J. COVID-19 pandemic and impact on hematopoietic stem cell transplantation. Bone Marrow Transplant 2020;55:2193-2195.
  • 25. RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020;383:2030-2040.
  • 26. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP, Marcadenti A, Kawano-Dourado L, Lisboa T, Junqueira DLM, de Barros E Silva PGM, Tramujas L, Abreu-Silva EO, Laranjeira LN, Soares AT, Echenique LS, Pereira AJ, Freitas FGR, Gebara OCE, Dantas VCS, Furtado RHM, Milan EP, Golin NA, Cardoso FF, Maia IS, Hoffmann Filho CR, Kormann APM, Amazonas RB, Bocchi de Oliveira MF, Serpa-Neto A, Falavigna M, Lopes RD, Machado FR, Berwanger O; Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med 2020;383:2041-2052.
  • 27. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, LaBar D, Lother SA, MacKenzie LJ, Drobot G, Marten N, Zarychanski R, Kelly LE, Schwartz IS, McDonald EG, Rajasingham R, Lee TC, Hullsiek KH. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020;383:517-525.
  • 28. Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother 2020;75:2013-2014.
  • 29. Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 2021;102:501-508.
APA civriz bozdag s, Cengiz Seval G, Yonal-Hindilerden I, Hindilerden F, Andic N, Baydar M, AYDIN KAYNAR L, Toprak S, GOKSOY H, balik aydin b, Demirci U, Can F, Ozkocaman V, GUNDUZ E, Guven Z, OZKURT Z, Demircioğlu S, Beksac M, İNCE İ, Yilmaz U, Eroğlu küçükdiler A, ABİSHOV E, Yavuz B, ATAS U, mutlu Y, bas v, Özkalemkaş F, Üsküdar Teke H, Gursoy V, ÇELİK S, Çiftçiler R, YAĞCI M, Topcuoglu P, Ceneli O, ABBASOV H, selim c, Ar M, YUCEL O, Sadri S, albayrak c, Demir A, Güler N, Keklik M, Terzi H, Doğan A, yegin z, Yuksel M, SADRİ S, yavasoglu İ, Beköz H, Aksu T, MARAL S, AKYAY A, Ozcan M, Gürman G, Unal S, Yavuz Y, Diz-Kucukkaya R, Ozsan G (2022). Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. , 43 - 54. 10.4274/tjh.galenos.2021.2021.0287
Chicago civriz bozdag sinem,Cengiz Seval Guldane,Yonal-Hindilerden Ipek,Hindilerden Fehmi,Andic Neslıhan,Baydar Mustafa,AYDIN KAYNAR LALE,Toprak Selami Kocak,GOKSOY HASAN,balik aydin berrin,Demirci Ufuk,Can Ferda,Ozkocaman Vildan,GUNDUZ Eren,Guven Zeynep Tugba,OZKURT ZÜBEYDE NUR,Demircioğlu Sinan,Beksac Meral,İNCE İDRİS,Yilmaz Umut,Eroğlu küçükdiler Ayşe hilal,ABİSHOV Elgün,Yavuz Boran,ATAS Unal,mutlu Yaşa gül,bas volkan,Özkalemkaş Fahir,Üsküdar Teke Hava,Gursoy Vildan,ÇELİK Serhat,Çiftçiler Rafiye,YAĞCI Münci,Topcuoglu Pervin,Ceneli Ozcan,ABBASOV HAMZA,selim cem,Ar Muhlis Cem,YUCEL ORHAN KEMAL,Sadri Sevil,albayrak canan,Demir Ahmet Muzaffer,Güler Nil,Keklik Muzaffer,Terzi Hatice,Doğan Ali,yegin zeynep arzu,Yuksel Meltem Kurt,SADRİ Soğol,yavasoglu İrfan,Beköz Hüseyin Saffet,Aksu Tekin,MARAL SENEM,AKYAY ARZU,Ozcan Muhit,Gürman Günhan,Unal Sule,Yavuz Yasemin,Diz-Kucukkaya Reyhan,Ozsan Guner Hayri Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. (2022): 43 - 54. 10.4274/tjh.galenos.2021.2021.0287
MLA civriz bozdag sinem,Cengiz Seval Guldane,Yonal-Hindilerden Ipek,Hindilerden Fehmi,Andic Neslıhan,Baydar Mustafa,AYDIN KAYNAR LALE,Toprak Selami Kocak,GOKSOY HASAN,balik aydin berrin,Demirci Ufuk,Can Ferda,Ozkocaman Vildan,GUNDUZ Eren,Guven Zeynep Tugba,OZKURT ZÜBEYDE NUR,Demircioğlu Sinan,Beksac Meral,İNCE İDRİS,Yilmaz Umut,Eroğlu küçükdiler Ayşe hilal,ABİSHOV Elgün,Yavuz Boran,ATAS Unal,mutlu Yaşa gül,bas volkan,Özkalemkaş Fahir,Üsküdar Teke Hava,Gursoy Vildan,ÇELİK Serhat,Çiftçiler Rafiye,YAĞCI Münci,Topcuoglu Pervin,Ceneli Ozcan,ABBASOV HAMZA,selim cem,Ar Muhlis Cem,YUCEL ORHAN KEMAL,Sadri Sevil,albayrak canan,Demir Ahmet Muzaffer,Güler Nil,Keklik Muzaffer,Terzi Hatice,Doğan Ali,yegin zeynep arzu,Yuksel Meltem Kurt,SADRİ Soğol,yavasoglu İrfan,Beköz Hüseyin Saffet,Aksu Tekin,MARAL SENEM,AKYAY ARZU,Ozcan Muhit,Gürman Günhan,Unal Sule,Yavuz Yasemin,Diz-Kucukkaya Reyhan,Ozsan Guner Hayri Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. , 2022, ss.43 - 54. 10.4274/tjh.galenos.2021.2021.0287
AMA civriz bozdag s,Cengiz Seval G,Yonal-Hindilerden I,Hindilerden F,Andic N,Baydar M,AYDIN KAYNAR L,Toprak S,GOKSOY H,balik aydin b,Demirci U,Can F,Ozkocaman V,GUNDUZ E,Guven Z,OZKURT Z,Demircioğlu S,Beksac M,İNCE İ,Yilmaz U,Eroğlu küçükdiler A,ABİSHOV E,Yavuz B,ATAS U,mutlu Y,bas v,Özkalemkaş F,Üsküdar Teke H,Gursoy V,ÇELİK S,Çiftçiler R,YAĞCI M,Topcuoglu P,Ceneli O,ABBASOV H,selim c,Ar M,YUCEL O,Sadri S,albayrak c,Demir A,Güler N,Keklik M,Terzi H,Doğan A,yegin z,Yuksel M,SADRİ S,yavasoglu İ,Beköz H,Aksu T,MARAL S,AKYAY A,Ozcan M,Gürman G,Unal S,Yavuz Y,Diz-Kucukkaya R,Ozsan G Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. . 2022; 43 - 54. 10.4274/tjh.galenos.2021.2021.0287
Vancouver civriz bozdag s,Cengiz Seval G,Yonal-Hindilerden I,Hindilerden F,Andic N,Baydar M,AYDIN KAYNAR L,Toprak S,GOKSOY H,balik aydin b,Demirci U,Can F,Ozkocaman V,GUNDUZ E,Guven Z,OZKURT Z,Demircioğlu S,Beksac M,İNCE İ,Yilmaz U,Eroğlu küçükdiler A,ABİSHOV E,Yavuz B,ATAS U,mutlu Y,bas v,Özkalemkaş F,Üsküdar Teke H,Gursoy V,ÇELİK S,Çiftçiler R,YAĞCI M,Topcuoglu P,Ceneli O,ABBASOV H,selim c,Ar M,YUCEL O,Sadri S,albayrak c,Demir A,Güler N,Keklik M,Terzi H,Doğan A,yegin z,Yuksel M,SADRİ S,yavasoglu İ,Beköz H,Aksu T,MARAL S,AKYAY A,Ozcan M,Gürman G,Unal S,Yavuz Y,Diz-Kucukkaya R,Ozsan G Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. . 2022; 43 - 54. 10.4274/tjh.galenos.2021.2021.0287
IEEE civriz bozdag s,Cengiz Seval G,Yonal-Hindilerden I,Hindilerden F,Andic N,Baydar M,AYDIN KAYNAR L,Toprak S,GOKSOY H,balik aydin b,Demirci U,Can F,Ozkocaman V,GUNDUZ E,Guven Z,OZKURT Z,Demircioğlu S,Beksac M,İNCE İ,Yilmaz U,Eroğlu küçükdiler A,ABİSHOV E,Yavuz B,ATAS U,mutlu Y,bas v,Özkalemkaş F,Üsküdar Teke H,Gursoy V,ÇELİK S,Çiftçiler R,YAĞCI M,Topcuoglu P,Ceneli O,ABBASOV H,selim c,Ar M,YUCEL O,Sadri S,albayrak c,Demir A,Güler N,Keklik M,Terzi H,Doğan A,yegin z,Yuksel M,SADRİ S,yavasoglu İ,Beköz H,Aksu T,MARAL S,AKYAY A,Ozcan M,Gürman G,Unal S,Yavuz Y,Diz-Kucukkaya R,Ozsan G "Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies." , ss.43 - 54, 2022. 10.4274/tjh.galenos.2021.2021.0287
ISNAD civriz bozdag, sinem vd. "Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies". (2022), 43-54. https://doi.org/10.4274/tjh.galenos.2021.2021.0287
APA civriz bozdag s, Cengiz Seval G, Yonal-Hindilerden I, Hindilerden F, Andic N, Baydar M, AYDIN KAYNAR L, Toprak S, GOKSOY H, balik aydin b, Demirci U, Can F, Ozkocaman V, GUNDUZ E, Guven Z, OZKURT Z, Demircioğlu S, Beksac M, İNCE İ, Yilmaz U, Eroğlu küçükdiler A, ABİSHOV E, Yavuz B, ATAS U, mutlu Y, bas v, Özkalemkaş F, Üsküdar Teke H, Gursoy V, ÇELİK S, Çiftçiler R, YAĞCI M, Topcuoglu P, Ceneli O, ABBASOV H, selim c, Ar M, YUCEL O, Sadri S, albayrak c, Demir A, Güler N, Keklik M, Terzi H, Doğan A, yegin z, Yuksel M, SADRİ S, yavasoglu İ, Beköz H, Aksu T, MARAL S, AKYAY A, Ozcan M, Gürman G, Unal S, Yavuz Y, Diz-Kucukkaya R, Ozsan G (2022). Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. Turkish Journal of Hematology, 39(1), 43 - 54. 10.4274/tjh.galenos.2021.2021.0287
Chicago civriz bozdag sinem,Cengiz Seval Guldane,Yonal-Hindilerden Ipek,Hindilerden Fehmi,Andic Neslıhan,Baydar Mustafa,AYDIN KAYNAR LALE,Toprak Selami Kocak,GOKSOY HASAN,balik aydin berrin,Demirci Ufuk,Can Ferda,Ozkocaman Vildan,GUNDUZ Eren,Guven Zeynep Tugba,OZKURT ZÜBEYDE NUR,Demircioğlu Sinan,Beksac Meral,İNCE İDRİS,Yilmaz Umut,Eroğlu küçükdiler Ayşe hilal,ABİSHOV Elgün,Yavuz Boran,ATAS Unal,mutlu Yaşa gül,bas volkan,Özkalemkaş Fahir,Üsküdar Teke Hava,Gursoy Vildan,ÇELİK Serhat,Çiftçiler Rafiye,YAĞCI Münci,Topcuoglu Pervin,Ceneli Ozcan,ABBASOV HAMZA,selim cem,Ar Muhlis Cem,YUCEL ORHAN KEMAL,Sadri Sevil,albayrak canan,Demir Ahmet Muzaffer,Güler Nil,Keklik Muzaffer,Terzi Hatice,Doğan Ali,yegin zeynep arzu,Yuksel Meltem Kurt,SADRİ Soğol,yavasoglu İrfan,Beköz Hüseyin Saffet,Aksu Tekin,MARAL SENEM,AKYAY ARZU,Ozcan Muhit,Gürman Günhan,Unal Sule,Yavuz Yasemin,Diz-Kucukkaya Reyhan,Ozsan Guner Hayri Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. Turkish Journal of Hematology 39, no.1 (2022): 43 - 54. 10.4274/tjh.galenos.2021.2021.0287
MLA civriz bozdag sinem,Cengiz Seval Guldane,Yonal-Hindilerden Ipek,Hindilerden Fehmi,Andic Neslıhan,Baydar Mustafa,AYDIN KAYNAR LALE,Toprak Selami Kocak,GOKSOY HASAN,balik aydin berrin,Demirci Ufuk,Can Ferda,Ozkocaman Vildan,GUNDUZ Eren,Guven Zeynep Tugba,OZKURT ZÜBEYDE NUR,Demircioğlu Sinan,Beksac Meral,İNCE İDRİS,Yilmaz Umut,Eroğlu küçükdiler Ayşe hilal,ABİSHOV Elgün,Yavuz Boran,ATAS Unal,mutlu Yaşa gül,bas volkan,Özkalemkaş Fahir,Üsküdar Teke Hava,Gursoy Vildan,ÇELİK Serhat,Çiftçiler Rafiye,YAĞCI Münci,Topcuoglu Pervin,Ceneli Ozcan,ABBASOV HAMZA,selim cem,Ar Muhlis Cem,YUCEL ORHAN KEMAL,Sadri Sevil,albayrak canan,Demir Ahmet Muzaffer,Güler Nil,Keklik Muzaffer,Terzi Hatice,Doğan Ali,yegin zeynep arzu,Yuksel Meltem Kurt,SADRİ Soğol,yavasoglu İrfan,Beköz Hüseyin Saffet,Aksu Tekin,MARAL SENEM,AKYAY ARZU,Ozcan Muhit,Gürman Günhan,Unal Sule,Yavuz Yasemin,Diz-Kucukkaya Reyhan,Ozsan Guner Hayri Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. Turkish Journal of Hematology, vol.39, no.1, 2022, ss.43 - 54. 10.4274/tjh.galenos.2021.2021.0287
AMA civriz bozdag s,Cengiz Seval G,Yonal-Hindilerden I,Hindilerden F,Andic N,Baydar M,AYDIN KAYNAR L,Toprak S,GOKSOY H,balik aydin b,Demirci U,Can F,Ozkocaman V,GUNDUZ E,Guven Z,OZKURT Z,Demircioğlu S,Beksac M,İNCE İ,Yilmaz U,Eroğlu küçükdiler A,ABİSHOV E,Yavuz B,ATAS U,mutlu Y,bas v,Özkalemkaş F,Üsküdar Teke H,Gursoy V,ÇELİK S,Çiftçiler R,YAĞCI M,Topcuoglu P,Ceneli O,ABBASOV H,selim c,Ar M,YUCEL O,Sadri S,albayrak c,Demir A,Güler N,Keklik M,Terzi H,Doğan A,yegin z,Yuksel M,SADRİ S,yavasoglu İ,Beköz H,Aksu T,MARAL S,AKYAY A,Ozcan M,Gürman G,Unal S,Yavuz Y,Diz-Kucukkaya R,Ozsan G Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. Turkish Journal of Hematology. 2022; 39(1): 43 - 54. 10.4274/tjh.galenos.2021.2021.0287
Vancouver civriz bozdag s,Cengiz Seval G,Yonal-Hindilerden I,Hindilerden F,Andic N,Baydar M,AYDIN KAYNAR L,Toprak S,GOKSOY H,balik aydin b,Demirci U,Can F,Ozkocaman V,GUNDUZ E,Guven Z,OZKURT Z,Demircioğlu S,Beksac M,İNCE İ,Yilmaz U,Eroğlu küçükdiler A,ABİSHOV E,Yavuz B,ATAS U,mutlu Y,bas v,Özkalemkaş F,Üsküdar Teke H,Gursoy V,ÇELİK S,Çiftçiler R,YAĞCI M,Topcuoglu P,Ceneli O,ABBASOV H,selim c,Ar M,YUCEL O,Sadri S,albayrak c,Demir A,Güler N,Keklik M,Terzi H,Doğan A,yegin z,Yuksel M,SADRİ S,yavasoglu İ,Beköz H,Aksu T,MARAL S,AKYAY A,Ozcan M,Gürman G,Unal S,Yavuz Y,Diz-Kucukkaya R,Ozsan G Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. Turkish Journal of Hematology. 2022; 39(1): 43 - 54. 10.4274/tjh.galenos.2021.2021.0287
IEEE civriz bozdag s,Cengiz Seval G,Yonal-Hindilerden I,Hindilerden F,Andic N,Baydar M,AYDIN KAYNAR L,Toprak S,GOKSOY H,balik aydin b,Demirci U,Can F,Ozkocaman V,GUNDUZ E,Guven Z,OZKURT Z,Demircioğlu S,Beksac M,İNCE İ,Yilmaz U,Eroğlu küçükdiler A,ABİSHOV E,Yavuz B,ATAS U,mutlu Y,bas v,Özkalemkaş F,Üsküdar Teke H,Gursoy V,ÇELİK S,Çiftçiler R,YAĞCI M,Topcuoglu P,Ceneli O,ABBASOV H,selim c,Ar M,YUCEL O,Sadri S,albayrak c,Demir A,Güler N,Keklik M,Terzi H,Doğan A,yegin z,Yuksel M,SADRİ S,yavasoglu İ,Beköz H,Aksu T,MARAL S,AKYAY A,Ozcan M,Gürman G,Unal S,Yavuz Y,Diz-Kucukkaya R,Ozsan G "Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies." Turkish Journal of Hematology, 39, ss.43 - 54, 2022. 10.4274/tjh.galenos.2021.2021.0287
ISNAD civriz bozdag, sinem vd. "Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies". Turkish Journal of Hematology 39/1 (2022), 43-54. https://doi.org/10.4274/tjh.galenos.2021.2021.0287